Inhibition of kynurenine 3-monooxygenase (KMO), an enzyme in the eukaryotic tryptophan catabolic pathway (that is, kynurenine pathway), leads to amelioration of Huntington's-disease-relevant phenotypes in yeast, fruitfly and mouse models 1-5 , as well as in a mouse model of Alzheimer's disease 3 . KMO is a flavin adenine dinucleotide (FAD)-dependent monooxygenase and is located in the outer mitochondrial membrane where it converts L-kynurenine to 3-hydroxykynurenine. Perturbations in the levels of kynurenine pathway metabolites have been linked to the pathogenesis of a spectrum of brain disorders 6 , as well as cancer 7,8 and several peripheral inflammatory conditions 9 . Despite the importance of KMO as a target for neurodegenerative disease, the molecular basis of KMO inhibition by available lead compounds has remained unknown. Here we report the first crystal structure of Saccharomyces cerevisiae KMO, in the free form and in complex with the tight-binding inhibitor UPF 648. UPF 648 binds close to the FAD cofactor and perturbs the local active-site structure, preventing productive binding of the substrate L-kynurenine. Functional assays and targeted mutagenesis reveal that the active-site architecture and UPF 648 binding are essentially identical in human KMO, validating the yeast KMO-UPF 648 structure as a template for structure-based drug design. This will inform the search for new KMO inhibitors that are able to cross the blood-brain barrier in targeted therapies against neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's diseases.
Inhibition of kynurenine 3-monooxygenase (KMO), an enzyme in the eukaryotic tryptophan catabolic pathway (that is, kynurenine pathway), leads to amelioration of Huntington's-disease-relevant phenotypes in yeast, fruitfly and mouse models [1] [2] [3] [4] [5] , as well as in a mouse model of Alzheimer's disease 3 . KMO is a flavin adenine dinucleotide (FAD)-dependent monooxygenase and is located in the outer mitochondrial membrane where it converts L-kynurenine to 3-hydroxykynurenine. Perturbations in the levels of kynurenine pathway metabolites have been linked to the pathogenesis of a spectrum of brain disorders 6 , as well as cancer 7, 8 and several peripheral inflammatory conditions 9 . Despite the importance of KMO as a target for neurodegenerative disease, the molecular basis of KMO inhibition by available lead compounds has remained unknown. Here we report the first crystal structure of Saccharomyces cerevisiae KMO, in the free form and in complex with the tight-binding inhibitor UPF 648. UPF 648 binds close to the FAD cofactor and perturbs the local active-site structure, preventing productive binding of the substrate L-kynurenine. Functional assays and targeted mutagenesis reveal that the active-site architecture and UPF 648 binding are essentially identical in human KMO, validating the yeast KMO-UPF 648 structure as a template for structure-based drug design. This will inform the search for new KMO inhibitors that are able to cross the blood-brain barrier in targeted therapies against neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's diseases.
There is great interest in the causative role of kynurenine pathway metabolites in neurodegenerative disorders such as Huntington's and Alzheimer's diseases 6 . Several of these metabolites are neuroactive: quinolinic acid (QUIN) is an excitotoxin 10,11 , 3-hydroxykynurenine (3-HK) generates free radicals 12 , xanthurenic and cinnabarinic acids activate metabotropic glutamate receptors 13, 14 and kynurenic acid (KYNA) is a neuroprotectant 6 . KMO lies at a critical branching point in the pathway between the synthesis of 3-HK/QUIN and KYNA ( Fig. 1a) and its activity has a role in the neurotoxic and neuroprotective potential of the pathway. In the brain, KMO is expressed at low levels in neurons 15 and is predominantly expressed in microglia 1, 16 , the resident immune cells of the CNS, suggesting a link between KMO function and inflammatory processes in the brain.
Inhibition of KMO activity leads to amelioration of several diseaserelevant phenotypes in yeast, fruitfly and mouse models [1] [2] [3] [4] [5] . Increased levels of KYNA relative to neurotoxic metabolites seem critical for this protection. Restoring endogenous levels of 3-HK to fruitflies lacking KMO activity eliminates this neuroprotection 4 , highlighting beneficial effects of 3-HK reduction due to KMO inhibition. In addition, pharmacological inhibition of KMO is neuroprotective in animal models of cerebral ischaemia 17, 18 , reduces dystonia in a genetic model of paroxysmal dyskinesia 19 , improves levodopa-induced dyskinesia in parkinsonian monkeys 20 and extends lifespan in a mouse model of cerebral malaria 21 . Therefore, inhibition of KMO activity is an attractive therapeutic strategy for several acute and chronic neurological diseases 6 .
Despite interest in targeting KMO only a few potent inhibitors are available, and none appreciably penetrate the blood-brain barrier in adult animals 3, 22 . One of these, UPF 648, has a half-maximum inhibitory concentration (IC 50 ) of 20 nM and provides protection against intrastriatal QUIN injections in kynurenine aminotransferase (KATII, also known as AADAT)-deficient mice 23 . UPF 648 treatment also shifts kynurenine pathway metabolism towards enhanced neuroprotective KYNA formation 4, 24 , and ameliorates disease-relevant phenotypes in a fruitfly model of Huntington's disease 4 . That known inhibitors do not cross the blood-brain barrier is an impediment to KMO-targeted drug discovery. KMO structures in complex with tightbinding inhibitors are required to design small-molecule inhibitors that can penetrate the blood-brain barrier. With this in mind, we determined the crystal structure of yeast KMO complexed with UPF 648. This enzyme-inhibitor structure can now be used to help develop new inhibitors of highly related human KMO.
We expressed full-length human KMO using the insect cell baculovirus system, which yielded small quantities (0.5 mg per litre of culture) of detergent-solubilized active KMO. The recombinant form had similar kinetic constants to native KMO from pig liver mitochondria 25 . UPF 648 binds tightly to recombinant KMO (inhibition constant (K i ) 5 56.7 nM). Poor stability and low expression yields, however, prevented crystallization. We therefore turned to S. cerevisiae KMO, which is related to human KMO (38% identity and 51% similarity). Expression of full-length S. cerevisiae KMO yielded a protein fragment (KMO(D396)) with a lower molecular weight than anticipated. Electrospray ionization mass spectrometry indicated proteolytic cleavage at residue 396. Subsequently, we isolated a KMO(D394) (residues 394-460 deleted) version of the enzyme engineered by site-directed mutagenesis (Methods) to define the cleavage point before crystallization (Supplementary Fig. 1 and Supplementary Table 1 ). The KMO(D394) enzyme was active ( Supplementary Figs 2 and 3 ), generated authentic 3-HK in high-performance liquid chromatography (HPLC)-based assays ( Fig. 1b) and was inhibited by UPF 648 (K i 5 74 nM) with a potency similar to that seen with human KMO ( Fig. 1b and Table 1 ).
The structure of the proteolysed form of yeast KMO (KMO(D396)) was determined using selenomethionine single anomalous diffraction (Protein Data Bank (PDB) codes 4J2W and 4J31). We also solved structures of KMO(D394) to 1.85 Å resolution. The final model contains residues 1-97 and 101-390 and the bound FAD cofactor. Both crystal forms contain a putative KMO dimer in the asymmetric unit ( Fig. 2a ). The KMO fold is similar to other flavin-dependent hydroxylase structures 26, 27 , with highest structural similarity to 2-methyl-3hydroxypyridine-5-carboxylic acid oxygenase 28 (root mean squared deviation, 2.3 Å over 310 Ca atoms; overall sequence identity, 16%; Q-score, 0.43; Z-score, 15.0). An overlay of individual KMO monomers reveals variation in the position of the carboxy-terminal a-helix, with most monomers showing disorder beyond residue 380. The linker region following the second strand of the antiparallel b-sheet involved in substrate binding is disordered, with large variations in the positions of residues 96-97 and 101-104. The relative position of the FADbinding domain and six-stranded antiparallel b-sheet domain is subject to minor variation, reminiscent of domain motion coupled to substrate binding in other members of this family 26 .
In absence of substrate, flexibility in relative positioning of both domains flanking the KMO active site is also reflected in distinct conformations observed for residues lining the active site ( Fig. 3) . The reface of the FAD is connected to solvent by a narrow water-filled cavity that runs perpendicular to the active-site cleft ( Supplementary Fig. 4 ). A structural water is located above the FAD C4a, mimicking the position of the C4a-peroxide intermediate formed upon reaction with oxygen. The dimethylbenzene moiety of the FAD isoalloxazine is protected from solvent by Lys 48 and the conserved residue Tyr 195 ( Supplementary Fig. 4 ). In absence of large protein rearrangements, this suggests that a 'waving flavin' motion as demonstrated in other FAD-dependent monooxygenases 29 is unlikely to occur in KMO during turnover.
We were unable to obtain a KMO complex with L-kynurenine (L-KYN) but succeeded in co-crystallizing with UPF 648 (Supplementary Table 3 , PDB code 4J36). The asymmetric unit contains a putative KMO dimer with one monomer containing UPF 648 bound in the active site, adjacent to the FAD re-face (Figs 2b and 3 ). The UPF 648 carboxylate is bound by conserved residues Arg 83 and Tyr 97 whereas the aromatic dichlorobenzene moiety is flanked by several hydrophobic residues Table 2 ). The chemical similarity of UPF 648 and L-KYN allowed modelling of L-KYN in the KMO active site (Methods). Modelling suggests that L-KYN is bound similarly, but without effect on the Pro 321-Gln 325 loop. The aromatic substrate moiety is located in the conserved hydrophobic pocket (residues Leu 221, Met 230, Ile 232, Leu 234, Phe 246, Pro 321, Phe 322) on the re-face of the flavin (Fig. 3) . Additional polar contacts are formed between the conserved Gln 325 and the L-KYN carbonyl group, and between the substrate aniline nitrogen atom and the FAD O4 atom. Whereas the amino acid carboxylate is bound by Arg 83 and Tyr 97, the amino group is devoid of direct interactions with protein in the model. An additional salt bridge may be made between the L-KYN amine and the side chain of Glu 102, which is located in a highly flexible region of KMO. However, this residue is often replaced by a glutamine in other KMO enzymes (Supplementary Fig. 5 ), suggesting that this interaction is not critical for enzyme activity. The model places the substrate C3 atom adjacent to the flavin C4a, where it is poised to attack the flavin C4a-peroxide intermediate (Fig. 4a ). All residues implicated by the KMO-L-KYN model as being involved in L-KYN binding are conserved across KMOs (Supplementary Fig. 5 ). We validated this model by mutating residue Arg 83 (replaced by Ala 83 and Met 83) and performing inhibitor binding/ kinetic assays (Fig. 4b) . Enzyme activity is compromised following mutation (25% and ,3% of wild-type activity for Ala 83 and Met 83 mutant KMO enzymes, respectively) as predicted by the KMO-L-KYN model. Mutation led to ,20-fold increase in dissociation constant (K d ) for the KMO-UPF 648 inhibitor complex, which implicates Arg 83 in inhibitor binding.
RESEARCH LETTER
Elucidation of the KMO crystal structure in free form and in complex with an established inhibitor is a major breakthrough for new KMO inhibitor design. This will permit docking screens using virtual compound libraries that may ultimately identify novel inhibitor scaffolds. Such studies will enable the design of new inhibitors that possess the selectivity and affinity to open up new opportunities for therapeutic intervention. Critically, this should inform the development of brain-penetrant KMO inhibitors. The KMO inhibitor Ro 61-8048 and prodrug JM6 have shown preclinical promise in animal models of neurodegeneration 2-4,16-20 , but they do not appreciably penetrate the blood-brain barrier. These compounds probably confer neuroprotection by inhibiting KMO in the blood and consequent active transport of L-KYN into the brain, ultimately yielding increased levels of the neuroprotective metabolite KYNA 3, 30 . As this neuroprotection seems to be independent of KMO inhibition in the brain and reduction of downstream neurotoxic metabolite levels 3 , delivery of KMO inhibitors directly to the CNS should provide critical additional therapeutic efficacy and broaden the scope of disorders amenable to targeting.
METHODS SUMMARY
Discrimination assays. Human and S. cerevisiae KMO were produced using baculovirus and Escherichia coli expression systems, respectively. HPLC was used to monitor inhibition of KMO by UPF 648 by monitoring formation of product 3-HK across a range of inhibitor UPF 648 concentrations (0-2 mM). Flavin fluorescence-emission measurements were used to determine K d for KMO ligands through ligand perturbation of the fluorescence of enzyme-bound FAD. Detailed protocols can be found in Methods. Crystallization and diffraction data collection. Crystals of S. cerevisiae KMO were obtained using the sitting-drop vapour-diffusion technique. Details describing the crystallogenesis can be found in Methods. Diffraction data from S. cerevisiae KMO crystals were collected from single cryo-frozen samples at the Diamond Light Source, Harwell, UK. A single-wavelength anomalous dispersion data set at the selenium edge was used for initial phase determination. Data collection and refinement statistics are presented in Supplementary Table 3 .
METHODS
Cloning, expression and purification of human full-length KMO. The gene encoding full-length human KMO was synthesized (GeneScript) and codon optimized for overexpression in mammalian cells. The gene was subcloned into the baculovirus transfer vector pAcGHLT-A-glutathione S-transferase as a NdeI-EcoRI fragment and transfected into Hi5 cells along with linearized baculovirus using the following sense and antisense primers: 59-GGCATATGCATGGACAG CAGCGTGATCCAGCGGAAG-39; 59-CCCGAATTCCTACCGGCTGATCAG GTTGCTG-39. Hi5 cells (1.5 3 10 6 ) were infected with recombinant virus for 72 h at 28 uC. A WAVE Bioreactor System (GE Healthcare Life Sciences) was used to grow batches of 5-litres of cell culture. Cultured cells were lysed in 20 mM potassium phosphate buffer, pH 7.5, 10% glycerol, 0.5% n-dodecyl b-D-maltoside (DDM), 150 mM NaCl, 7 mM 2-mercaptoethanol and 50 mM FAD supplemented with protease inhibitors (Sigma-Aldrich). Soluble lysate was incubated with 3 ml pre-equilibrated glutathione uniflow resin (Clontech). The resin was then packed and washed with buffer B (20 mM potassium phosphate buffer, pH 7.5, 10% glycerol, 0.012% DDM, 150 mM NaCl, 7 mM 2-mercaptoethanol, 50 mM FAD). Fractions (0.5 ml) were eluted with buffer C (buffer B 1 33 mM glutathione) and fractions containing KMO pooled, concentrated and loaded onto a Superdex 200 (10/30) size-exclusion chromatography column. Pure KMO was pooled and stored at 280 uC. Cloning, expression and purification of S. cerevisiae KMO. A synthetic gene (BNA4, UniProtKB accession number P38169) encoding S. cerevisiae KMO was codon optimized for overexpression in E. coli (GeneScript). The gene was subcloned into pET15b and pET24b (Merck) as a NdeI-XbaI fragment for overexpression in E. coli strain BL21(DE3). A deletion variant of KMO (KMO(D-394)) and singleamino-acid variants of this deletion (KMO(D394, R83A) and KMO(D394, R83M)) were generated by site-directed mutagenesis (QuikChange, Strategene, Agilent Technologies). Sense and antisense primers are shown in Supplementary Table 1 . Amplification conditions were as follows: denaturation at 95 uC for 30 s, followed by 16 cycles of amplification at 95 uC (30 s), 55 uC (60 s) and 68 uC (7 min). PCR products were incubated for 1 h to digest methylated template DNA and then transformed into XL1-Blue supercompetent cells (Stratagene, Agilent Technologies). Transformed bacterial colonies were isolated and mutated genes were identified by DNA sequencing (Eurofins MWG Operon) to verify presence of desired, and lack of spurious changes, to the DNA sequence.
Transformed bacterial cells were grown overnight at 37 uC in lysogeny broth (LB; 0.75 l) containing 100 mg ml 21 ampicillin. Cultures were grown at 37 uC to an attenuance of ,0.3, and the temperature was then reduced to 27 uC. Cells were induced (0.1 mM isopropyl-b-D-thiogalactopyranoside; IPTG) and grown (16-20 h) at 27 uC. Cells were lysed in buffer A (20 mM potassium phosphate buffer, pH 7.5, 10% glycerol, 300 mM NaCl, 50 mM FAD) containing protease inhibitors. Soluble lysate was loaded onto a 5-ml HisTrap FF Ni Sepharose 6 Fast Flow column (GE Healthcare) pre-equilibrated with buffer A. Protein was eluted using a 50-250-mM imidazole linear gradient. Yellow fractions containing partially purified KMO were pooled and diluted ten times in buffer B to reduce salt and imidazole concentration. Protein was subsequently loaded onto a 10-ml blue Sepharose 6 fast flow column (GE Healthcare) equilibrated with buffer B. The protein was eluted using a linear gradient to 2.5 M NaCl prepared in buffer B. Fractions containing KMO were pooled and diluted tenfold in buffer B to reduce the NaCl concentration. Protein was concentrated and chromatographed using a Superdex 200 10/300 GL column (GE Healthcare) equilibrated with buffer C (25 mM ammonium acetate buffer, pH 7.0, 150 mM NaCl, 7 mM 2-mercaptoethanol). Pure fractions were collected and stored at 280 uC. Incorporation of selenomethionine into S. cerevisiae KMO. Expression of selenomethionine-labelled protein was achieved by inhibiting methionine biosynthesis shortly before induction of KMO expression by adding high concentrations of isoleucine, leucine, phenylalanine, lysine and threonine to the cell culture. Transformed E. coli cells containing the S. cerevisiae KMO expression plasmid were grown in LB media at 37 uC to late exponential phase, collected and then resuspended in M9 minimal media and grown until mid-log phase. At that point lysine, phenylalanine, threonine (100 mg l 21 each) and selenomethionine, isoleucine, leucine and valine (50 mg l 21 each) were added to the culture and induced 15 min after addition of amino acids with 0.1 mM IPTG. The culture was grown for 12-16 h. Purification of selenomethionine-incorporated S. cerevisiae KMO was as described for conventional S. cerevisiae KMO. Enzyme assays. Steady-state kinetic parameters for KMO were obtained by initial rate measurements of enzyme activity. KMO catalyses the NADPH-dependent hydroxylation of L-KYN to 3-HK and the enzymatic reaction can be monitored by following the decrease in absorbance of NADPH at 340 nm. Rate assays were carried out with 1-cm path-length quartz microcuvette at 37 uC for human KMO and 30 uC for S. cerevisiae KMO. Pure enzyme (0.2-1.0 mM) was added to 200 ml reaction buffer (20 mM potassium phosphate buffer, pH 8.0, 7 mM 2-mercaptoethanol) containing different concentrations of NADPH and L-KYN (Sigma-Aldrich) and the timedependent absorbance change at 340 nm was recorded using a using a UV-Vis Cary Eclipse spectrophotometer (Agilent Technologies). Assays at each reaction condition were performed in triplicate. Apparent Michaelis constants (K m ) for L-KYN and NADPH were determined by varying the concentration of the first substrate at a constant concentration of the second substrate and vice versa. Reaction data were fitted to the standard Michaelis-Menten equation using Origin Software (OriginLab).
KMO inhibition by UPF 648 was measured by monitoring the formation of the product 3-HK by C 18 reversed-phase HPLC. Enzyme (100 nM) was incubated at 37 uC in 1 ml reaction buffer (20 mM potassium phosphate buffer, pH 8.5, 7 mM 2-mercaptoethanol) with 2 mM NADPH, 500 mM L-KYN and different concentrations (0-2 mM) of UPF 468. The reaction was stopped with 8% trifluoroacetic acid added at different time points during the assay. Precipitated protein was removed by centrifugation, and the supernatant was analysed by C 18 reversedphase HPLC equilibrated with 50 mM ammonium acetate, pH 3.0, containing 1% methanol and 0.1% heptanesulphonic acid; elution from the column was with 50 mM ammonium acetate, pH 4.5, containing 5% methanol and 0.5% heptanesulphonic acid, and monitored at 229 nm. 3-HK was quantified by comparison with a 3-HK calibration curve. Each experiment was performed in triplicate. Data were fitted to the Morrison equation:
in which v 0 is the enzyme activity without inhibitor, v i is the enzyme activity at ligand concentration I, [E] is the enzyme concentration, [I] is the inhibitor concentration and K i is the inhibition constant.
Ligand-binding assays. Fluorescence-emission measurements were performed using a Cary Eclipse Fluorimeter (Agilent Technologies) to determine enzymeligand K d for KMO ligands, exploiting ligand perturbation of flavin (enzymebound FAD) fluorescence. Excitation light was provided from a xenon light source and excitation and emission slit widths were 5 nm. The perturbation in FAD fluorescence emission was followed at 520 nm using an excitation wavelength of 450 nm and excitation spectra were recorded from 470 to 700 nm. L-KYN and UPF 648 were titrated into a 5-mM solution of KMO (20 mM potassium phosphate buffer, pH 8, 50 mM NaCl, 7 mM 2-mercaptoethanol) at 25 uC. K d was calculated by fitting data for the difference in fluorescence emission measured for KMOligand complexes and free KMO at 520 nm divided by the maximum emission versus the ligand concentration (equation (2)). This equation is a variation of Morrison equation used in equation (1) and is used for tight-binding ligands or when K d values are similar in magnitude to the concentration of enzyme used, in which case substantial amounts of both enzyme and ligand are consumed in forming the EX complex as the titration progresses. All data fitting was done using Origin software (OriginLab).
In equation (2), E obs represents the fluorescence-emission difference at each ligand concentration, X; E max is the maximum emission change at saturating ligand concentrations, [E] is the enzyme concentration and K d the dissociation constant for the ligand bound to the enzyme. Hydrogen peroxide quantification. Measurements to observe the formation of hydrogen peroxide from the DKMO-394-UPF 648 inhibitor complex were performed using a horseradish peroxidase (HRP) assay. Steady-state assays were performed as described above to calculate the NADPH consumption rate in the presence and absence of an excess of UPF 648 (30 mM 
